72 active not recruiting, 60 completed, 41 recruiting, 30 unknown. 251 Phase 2, 38 Phase 1, 4 Phase 3.
Follow olaparib: new trials by email Literature Review of olaparib trials Research Report on olaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes Olaparib + durvalumab - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 40 | 2027-01-01 | 2026-11-16 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
| Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer Olaparib - Solid Tumor | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 30 | 2026-09-01 | 2025-12-11 |
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) Temozolomide, Olaparib - Breast Cancer Triple Negative | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 40 | 2026-04-01 | 2025-12-15 |
| QLS5132 Combination Therapy in Advanced Solid Tumors QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 626 | 2026-04-01 | 2026-03-06 |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer Iparomlimab and Tuvonralimab (QL1706)Injection, paclitaxel, carboplatin - Ovarian Cancers | Phase 2 | Not yet recruiting | Jiangsu Cancer Institute & Hospital | 50 | 2026-02-01 | 2026-02-12 |
| QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) QL1706 + olaparib - Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 79 | 2025-08-30 | 2025-08-11 |
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer | Phase 2 | Recruiting | AbbVie | 377 | 2025-07-30 | 2026-10-01 |
| Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer QL1706 Plus Olaparib - Triple-Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 46 | 2025-06-30 | 2025-06-05 |
| Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity Dapagliflozin 10 MG Oral Tablet, Placebo Oral Tablet - Solid Tumors, Cisplatin Nephrotoxicity | Phase 2 | Recruiting | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 46 | 2025-05-07 | 2026-03-11 |
| The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer Olaparib - Ovarian Cancer, Epithelial Cancer | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 55 | 2025-05-01 | 2026-03-10 |
| A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) Pembrolizumab, Paclitaxel, Carboplatin - Early Triple Negative Breast Cancer | Phase 2 | Withdrawn | Merck Sharp & Dohme LLC | 2025-03-26 | 2026-02-19 | |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) Patritumab deruxtecan, Pembrolizumab, Paclitaxel - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 372 | 2025-03-20 | 2026-11-12 |
| FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) FPI-2265, Olaparib - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | Fusion Pharmaceuticals Inc. | 85 | 2025-02-26 | 2026-11-06 |
| Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer Pembrolizumab, Olaparib - Pancreatic Cancer | Phase 2 | Active not recruiting | Cambridge University Hospitals NHS Foundation Trust | 20 | 2025-02-26 | 2026-10-30 |
| Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer AK112 low dose, Chemotherapy, Olaparib - Platinum-sensitive Ovarian Cancer | Phase 2 | Recruiting | Akeso | 150 | 2025-02-17 | 2025-04-16 |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 | 2025-12-01 | |
| Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Olaparib + Elacestrant, Olaparib - Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 2 | Recruiting | GBG Forschungs GmbH | 176 | 2024-12-13 | 2025-12-01 |
Showing 20 of 251. Sign in to see all of them.
Ovarian Neoplasms (43) · Breast Neoplasms (35) · Prostatic Neoplasms (20) · Triple Negative Breast Neoplasms (20) · Fallopian Tube Neoplasms (15) · Neoplasms (11) · Endometrial Neoplasms (10) · Small Cell Lung Carcinoma (9) · Glioma (8) · Stomach Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Ovarian Epithelial (7) · Fanconi Anemia, Complementation Group D1 (7) · Neoplasm Metastasis (7) · Pancreatic Neoplasms (7)
National Cancer Institute (NCI) (35) · AstraZeneca (20) · Memorial Sloan Kettering Cancer Center (7) · Merck Sharp & Dohme LLC (7) · M.D. Anderson Cancer Center (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Gustave Roussy, Cancer Campus, Grand Paris (5) · Institute of Cancer Research, United Kingdom (4) · University Health Network, Toronto (4) · University of Washington (4) · Dana-Farber Cancer Institute (3) · Seoul National University Hospital (3) · UNICANCER (3) · University of Michigan Rogel Cancer Center (3) · ARCAGY/ GINECO GROUP (2)
United States (131) · Spain (37) · United Kingdom (32) · Canada (28) · France (28) · Germany (22) · South Korea (22) · Italy (20) · Australia (16) · China (16) · Israel (14) · Japan (13) · Netherlands (13) · Puerto Rico (11) · Poland (10)
Jane Robertson, BSc, MBCHB, MD (6) · Patricia M LoRusso (3) · Amit Oza, M.D. (2) · Andrew Tutt, PhD MRCP FRCR (2) · Joseph W Kim (2) · Joyce F Liu (2) · Jung-min Lee (2) · Kosei Hasegawa, MD, PhD (2) · Michael Schweizer (2) · Adam Crystal, MD, PhD (1) · Alexander B Olawaiye, MD (1)
PMID 35170751, PMID 26961146, PMID 23922302, PMID 19238149, PMID 34904813, PMID 37185961, PMID 39695768, PMID 42686334, PMID 42820295, PMID 20609467, PMID 20609468, PMID 21796368, PMID 21862407, PMID 22198468, PMID 22452356, PMID 22623692, PMID 22649152, PMID 23810467, PMID 24882434, PMID 25218906, PMID 25374341, PMID 25481791, PMID 25554012, PMID 26410619, PMID 26510020, PMID 26723501, PMID 27062051, PMID 27324108, PMID 27406346, PMID 27406347, PMID 27617661, PMID 27824811, PMID 28851423, PMID 30514390, PMID 30700568, PMID 31345267, PMID 31401903, PMID 31413177, PMID 31538815, PMID 31806540, PMID 32031889, PMID 32053137, PMID 32067679, PMID 32073956, PMID 32101663, PMID 32379297, PMID 32450725, PMID 32701140, PMID 32771088, PMID 32778095
2016 (8), 2018 (8), UM1CA186689 (8), 2017 (7), 2023 (6), U10CA180868 (6), UM1CA186709 (5), 2015 (3), U10CA180821 (3), UM1CA186644 (3), UM1CA186686 (3), 2019 (2), P30CA015704 (2), U10CA180820 (2), U10CA180886 (2)